DULCOLAX SUPPOSITORY 10 mg

Pays: Singapour

Langue: anglais

Source: HSA (Health Sciences Authority)

Ingrédients actifs:

BISACODYL

Disponible depuis:

OPELLA HEALTHCARE SINGAPORE PTE. LTD.

Code ATC:

A06AB02

Dosage:

10 mg

forme pharmaceutique:

SUPPOSITORY

Composition:

BISACODYL 10 mg

Mode d'administration:

RECTAL

Type d'ordonnance:

General Sale List

Fabriqué par:

Istituto De Angeli S.r.l.

Statut de autorisation:

ACTIVE

Date de l'autorisation:

1989-04-28

Notice patient

P a g e
 | 1 

DULCOLAX
®

abcd

SUPPOSITORIES 

COMPOSITION 
1 paediatric suppository contains   

5 mg 
1  suppository contains    

10 mg 
4,4’-diacetoxy-diphenyl-(pyridyl-2)-methane (= bisacodyl) 

PRODUCT DESCRIPTIONS 
Dulcolax Suppositories 5mg for children: Smooth, white, torpedo-shaped
suppositories with a 
‘chimney’ in the base. 
Dulcolax Suppositories 10mg for adults: White
or slightly yellowish, torpedo-shaped suppositories with 
a smooth or slightly unctuous surface and a “chimney” in the
base. 

PROPERTIES  
Bisacodyl is a locally acting laxative from the diphenylmethane
derivatives group having a dual action. 
As a contact laxative, for which also antiresorptive hydragogue
effects have been described, bisacodyl 
stimulates after hydrolysis in the large intestine, the mucosa
of both the large intestine and of the 
rectum. Stimulation of the mucosa of the large intestine
results in colonic peristalsis with promotion of 
accumulation of water, and consequently electrolytes, in the
colonic lumen. This results in a 
stimulation of defecation, reduction of transit time and softening
of the stool. Stimulation of the rectum 
causes increased motility and a feeling of rectal fullness. The
rectal effect may help to restore the “call 
to stool” although its clinical relevance remains to be
established. 

PHARMACOKINETICS  
Following
either oral or rectal administration, bisacodyl is rapidly hydrolyzed
to the active principle bis-(p-
hydroxyphenyl)-pyridyl-2-methane
(BHPM), mainly by esterases of the enteric mucosa. 
Administration as an enteric coated tablet was found to result in
maximum BHPM plasma 
concentrations between 4 - 10 hours post administration
whereas the laxative effect occurred between 6 
- 12 hours post administration. In contrast, following th

Résumé des caractéristiques du produit

Composition
1 paediatric suppository contains
5 mg
1 suppository contains
10 mg
4,4’-diacetoxy-diphenyl-(pyridyl-2)-methane
(= bisacodyl)
Product Descriptions
Dulcolax Suppositories 5mg for children:
Smooth, white, torpedo-shaped suppositories
with a ‘chimney’ in the base.
Dulcolax Suppositories 10mg for adults: White
or slightly yellowish, torpedo-shaped
suppositories with a smooth or slightly
unctuous surface and a “chimney” in the base.
Pharmacological Properties
ATC code: A06AB02
Bisacodyl is a locally acting laxative from the
diphenylmethane derivatives group having
a dual action. As a contact laxative, for which
also antiresorptive hydragogue effects have
been described, bisacodyl stimulates after
hydrolysis in the large intestine, the mucosa of
both the large intestine and of the rectum.
Stimulation of the mucosa of the large intestine
results in colonic peristalsis with promotion of
accumulation of water, and consequently
electrolytes, in the colonic lumen. This results
in a stimulation of defecation, reduction of
transit time and softening of the stool.
Stimulation of the rectum causes increased
motility and a feeling of rectal fullness. The
rectal effect may help to restore the “call to
stool” although its clinical relevance remains
to be established.
As a laxative that acts on the colon, bisacodyl
specifically stimulates the natural evacuation
process in the lower region of the
gastrointestinal tract. Therefore, bisacodyl is
ineffective in altering the digestion or
absorption of calories or essential nutrients in
the small intestine
Pharmacokinetics
Following either oral or rectal administration,
bisacodyl is rapidly hydrolyzed to the active
principle bis-(p- hydroxyphenyl)-pyridyl-2-
methane (BHPM), mainly by esterases of the
enteric mucosa.
Administration as an enteric coated tablet was
found to result in maximum BHPM plasma
concentrations between 4 - 10 hours post
administration whereas the laxative effect
occurred between 6 - 12 hours post
administration. In contrast, following the
ad